Ewing's Sarcoma Clinical Trial
Official title:
Randomized Phase II Study of Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) With or Without ImmTher for Newly Diagnosed High Risk Ewing's Sarcoma
Objectives:
1. To determine if dose intensive Vincristine, Doxorubicin, Cyclophosphamide and
Dexrazoxane (VACdxr) with or without ImmTherTM can improve the 2-year disease-free
survival seen with standard VAC therapy.
2. To evaluate the feasibility and describe the toxicity associated with VACdxr.
3. To evaluate the feasibility and describe the toxicity of administering ImmTherTM on a
weekly basis for 50- 52 weeks.
4. To determine which therapy (VACdxr+ or VACdxr-) is worthy of further evaluation.
Patients will be assigned at random (as by the toss of a coin) to receive 1 of 2 treatments.
Arm A: VACdxr will be given over 2 days through a needle in a vein. On day 1, vincristine
will be given over 15 minutes, and doxorubicin will be given over 30 minutes.
Dexrazoxane will be given 30 minutes before doxorubicin; this drug protects the heart from
damage by doxorubicin. Cyclophosphamide will be given once a day on days 1 and 2. This will
make up 1 cycle of VACdxr treatment; the cycle will be repeated every 3 weeks for up to 6
cycles.
To prevent some side effects of VACdxr, the drugs Mesna and Neupogen/or Neulasta will also be
given. Mesna helps prevent bladder damage. Neupogen is a growth factor that stimulates the
body to make more white blood cells. Neulasta is a growth factor related to Neupogen.
After cycle 3, surgery may be done to remove any tumor that remains. The principal
investigator will also decide whether radiation treatment should be done. If so, patients
will receive radiation therapy.
Starting 1 month after all treatment is done, patients will receive ImmTher. ImmTher
stimulates the body's white blood cells to attack and kill tumor cells. The drug will be
given through a needle in a vein over 1 hour, every week for 1 year.
Arm B: Patients will be treated the same as patients in Arm A, except that they will not
receive ImmTher.
Patients may have to stay in the hospital during VACdxr treatment and after surgery. Patients
will receive ImmTher in the outpatient clinic.
Before treatment starts, patients will have a complete exam including blood and urine tests
and an EKG and ECHO or multiple gated acquisition scan (MUGA) (heart function tests). X-rays
and CT, MRI, bone marrow aspiration, and bone scans will be done. Women will have a pregnancy
test.
After each treatment with drugs, after surgery, and after radiation treatment, patients will
have checkups. These will include blood and urine tests and sometimes x-rays.
After cycle 3 of VACdxr, patients will have chest x-ray and x-ray of primary tumor. CT chest,
MRI, bone marrow aspiration and bone scans will be done after 3 cycles as indicated. These
tests will be done to record and measure tumors.
After treatment stops, patients will return for checkups every 3 months for 2 years.
This is an investigational study. ImmTher is an investigational agent. All other study drugs
are approved by the U.S. Food and Drug Administration. As many as 104 patients will take part
in the study; about 95 of these will be treated at M.D. Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01734863 -
Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients
|
Phase 3 | |
Completed |
NCT01674101 -
Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy
|
N/A | |
Completed |
NCT02736565 -
Pbi-shRNAâ„¢ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
|
Phase 1 | |
Completed |
NCT00563680 -
QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors
|
Phase 2 | |
Completed |
NCT00987636 -
Study in Localized and Disseminated Ewing Sarcoma
|
Phase 3 | |
Completed |
NCT02890758 -
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
|
Phase 1 | |
Completed |
NCT01583543 -
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
|
Phase 2 | |
Terminated |
NCT01313884 -
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
|
Phase 2 | |
Completed |
NCT01696669 -
Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults
|
Phase 2 | |
Completed |
NCT00004853 -
Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy
|
Phase 1 | |
Terminated |
NCT00568464 -
Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)
|
Phase 2 | |
Completed |
NCT00001686 -
Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases
|
||
Completed |
NCT00492141 -
Aerosol L9-NC and Temozolomide in Ewing's Sarcoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00541411 -
Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma
|
N/A | |
Completed |
NCT02063022 -
Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma
|
Phase 3 | |
Completed |
NCT01598454 -
Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
|
Phase 1 | |
Recruiting |
NCT03442465 -
Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
|
||
Completed |
NCT02511132 -
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
|
Phase 2 | |
Completed |
NCT00923650 -
Informed Consent in Pediatric Cancer Trials
|
N/A | |
Completed |
NCT01962103 -
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
|
Phase 1/Phase 2 |